Significance of blood serum catalase activity and malondialdehyde level for survival prognosis of ovarian cancer patients

Medicina (Lithuania)

Volumn 50, Issue 4, 2014, Pages 204-208

  Didžiapetriene, Janina ^a,b   Bublevič, Jaroslav ^a,b   Smailyte, Giedre ^a   Kazbariene, Birute ^a   Stukas, Rimantas ^b  

^a NATIONAL CANCER INSTITUTE   (Lithuania)

^b VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Catalase; Malondialdehyde; Ovarian cancer; Oxidative stress; Survival

Indexed keywords

CATALASE; MALONALDEHYDE; TUMOR MARKER;

ADULT; AGED; BLOOD; CANCER STAGING; FEMALE; HUMAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; OXIDATIVE STRESS; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BIOMARKERS, TUMOR; CATALASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALONDIALDEHYDE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; OXIDATIVE STRESS; PROGNOSIS;

EID: 84923821123     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medici.2014.09.001     Document Type: Article

References (24)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013, available at: http://globocan.iarc.fr.
2. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Increasing cancer survival in Europe in the first decade of the 21st century: results of the EUROCARE-5 study. Lancet Oncol 2014;15:23-34.
3. Bast Jr RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 2007;174:91-100.
4. Isonishi S, Suzuki M, Nagano H, Takagi K, Shimauchi M, Kawabata M, et al. A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer. J Gynecol Oncol 2013;24:154-9.
5. Palmieri C, Gojis O, Rudraraju B, Stamp-Vincent C, Wilson D, Langdon S, et al. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br J Cancer 2013;108:2039-44.
6. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D, et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007;25:852-61.
7. Qiu JJ, Guo JJ, Lv TJ, Jin HY, Ding JX, Feng WW, et al. Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer. Tumour Biol 2013;34:2971-5.
8. El Behery MM, Seksaka MA, Ibrahiem MA, Saleh HS, El Alfy Y. Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet 2013;288:1371-6.
9. Kasapović J, Pejić S, Todorović A, Stojiljković V, Pajović SB. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages. Cell Biochem Funct 2008;26:723-30.
10. Bakan E, Taysi S, Polat MF, Dalga S, Umudum Z, Bakan N, et al. Nitric oxide levels and lipid peroxidation in plasma of patients with gastric cancer. Jpn J Clin Oncol 2002;32:162-6.
11. Salzman R, Pácal L, Tomandl J, Kanková K, Tóthová E, Gál B, et al. Elevated malondialdehyde correlates with the extent of primary tumor and predicts poor prognosis of oropharyngealcancer. Anticancer Res 2009;29:4227-31.
12. Farias J, Furtado F, Guimaraes S, Silva Filho AR, Vasconcelos PR. Oxidative stress parameters in women with breast cancer undergoing neoadjuvant chemotherapy and treated with nutraceutical doses of oral glutamine. Acta Cir Bras 2011;26(1):82-7.
13. Panis C, Herrera A, Victorino V, Campos FC, Freitas LF, De Rossi T, et al. Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 2012;133:89-97.
14. Gerber M, Astre C, Segala C, Saintot M, Scali J, Simony-Lafontaine J, et al. Oxidant-antioxidant status alterations in cancer patients: relationship to tumor progression. J Nutr 1996;126:1201S-7.
15. Gönenç A, Erten D, Aslan S, Akinci M, Simsek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign beast disease. Cell Biol Int 2006;30:376-80.
16. Peluso M, Munnia A, Risso G, Catarzi S, Piro S, Ceppi M, et al. Breast fine-needle aspiration malondialdehyde deoxyguanosine adduct in breast cancer. Free Radic Res 2011;45:477-82.
17. Sener DE, Gönenç A, Akinci M, Torun M. Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct 2007;25:377-82.
18. Zhang S, Qi L, Li M, Zhang D, Zhang D, Xu S, et al. Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J Exp Clin Cancer Res 2008;27:62.
19. Leuratti C, Watson MA, Deag EJ, Welch A, Singh R, Gottschalg E, et al. Detection of malondialdehyde DNA adducts in human colorectal mucosa: relationship with diet and the presence of adenomas. Cancer Epidemiol Biomarkers Prev 2002;11:267-73.
20. Chole RH, Patil RN, Basak A, Palandurkar K, Bhowate R. Estimation of serum malondialdehyde in oral cancer and precancer and its association with healthy individuals, gender, alcohol, and tobacco abuse. J Cancer Res Ther 2010;4:487-91.
21. Gupta A, Srivastava S, Prasad R, Natu SM, Mittal B, Negi MP, et al. Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response. Respirology 2010;15:349-56.
22. Polat MF, Taysi S, Gul M, Cikman O, Yilmaz I, Bakan E, et al. Oxidant/antioxidant status in blood of patients with malignant breast tumour and benign breast disease. Cell Biochem Funct 2002;4:327-31.
23. Alagöl H, Erdem E, Sancak B, Turkmen G, Camlibel M, Bugdayci G. Nitric oxide biosynthesis and malondialdehyde levels in advanced breast cancer. Aust N Z J Surg 1999;69:647-50.
24. Didziapetriene J, Kazbariene B, Surinenaite B, Krikstaponiene A, Ulys A, Uleckiene S, et al. Antioxidative system parameters and level of IL-18 after surgery in patients with renal cell carcinoma according to gender. Acta Physiol Hung 2013;100:107-14.